论文部分内容阅读
目的：采用雷公藤对角膜移植排斥反应进行实验性治疗。 方法以 Ｗｉｓｔａｒ大鼠异种角膜异位移植为模型，将 ３６只鼠随机分为治疗组及对照组，并在术后ｄ２、ｄ５、ｄ７、ｄ１０、ｄ１４分别取出植片做病理切片，检测外周血Ｔ淋巴细胞亚群及Ｔ淋巴细胞集落形成数。 结果雷公藤可推迟排斥反应的发生时间（排斥时间 ７．５±１．０７ｄ，对照组 ５．４±０． ９７ｄ）；有明显减少外周血中辅助 Ｔ淋巴细胞百分率的作用（术后 ｄ５治疗组 ＣＤ４＋／ＣＤ８＋为 １． ４２±０． ２７，对照组为１， ９６±０． ２６）；对大鼠外周血 Ｔ淋巴细胞集落形成能力无明显影响。 结论雷公藤多甙是一种有效的免疫抑制剂，能明显抑制角膜移植排斥反应发生时间及 ＣＤ４＋／ＣＤ８＋比值的上升。
Objective: Tripterygium wilfordii corneal graft rejection experimental experimental treatment. Methods Wistar rats heterotopic corneal heterotopic transplantation model, 36 rats were randomly divided into treatment group and control group, and the rats were sacrificed on day 2, day d5, day d7, day d10 and day d14 for pathological examination. T lymphocyte subsets and T lymphocyte colony forming number. Results Tripterygium could delay the occurrence of rejection (7.5 ± 1.07 days of rejection, 5.4 ± 0.97 days of control), and significantly reduce the percentage of helper T lymphocytes in peripheral blood (postoperative d5 treatment Group CD4 + / CD8 + 1.42 ± 0.27, the control group was 1 96 ± 0.26); had no significant effect on colony-forming ability of peripheral blood T lymphocytes in rats. Conclusion Tripterygium glycosides is an effective immunosuppressive agent, which can significantly inhibit the time of corneal graft rejection and the increase of CD4 + / CD8 + ratio.